These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7427961)

  • 21. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
    Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
    Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen responders selection by computerized contact thermography in benign breast disease.
    Cupceancu B; Mogoş I; Cotruţă C
    Endocrinologie; 1986; 24(2):115-22. PubMed ID: 3738400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.
    Wilkinson PM; Ribiero GG; Adam HK; Kemp JV; Patterson JS
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):33-5. PubMed ID: 7160042
    [No Abstract]   [Full Text] [Related]  

  • 25. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.
    Adam HK; Patterson JS; Kemp JV
    Cancer Treat Rep; 1980; 64(6-7):761-4. PubMed ID: 7427960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
    Buzdar AU; Hortobagyi GN; Frye D; Ho D; Booser DJ; Valero V; Holmes FA; Birmingham BK; Bui K; Yeh C
    J Clin Oncol; 1994 Jan; 12(1):50-4. PubMed ID: 8270984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicentre trial to compare a loading dose regimen of tamoxifen ('Nolvadex') with conventional dosing in the treatment of advanced breast cancer. The British Tamoxifen Study Group.
    Spooner D; Fairlamb D; Fermont D
    Clin Oncol (R Coll Radiol); 1991 May; 3(3):133-6. PubMed ID: 2069877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
    Tormey DC; Lippman ME; Edwards BK; Cassidy JG
    Ann Intern Med; 1983 Feb; 98(2):139-44. PubMed ID: 6824247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor response of breast cancer to tamoxifen.
    McDonald PJ; Carpenter R; Royle GT; Taylor I
    Postgrad Med J; 1990 Dec; 66(782):1029-31. PubMed ID: 2084647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.
    Manni A; Arafah BM
    Cancer; 1981 Aug; 48(4):873-5. PubMed ID: 7272931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinopathy caused by treatment with tamoxifen in low dosage.
    Vinding T; Nielsen NV
    Acta Ophthalmol (Copenh); 1983 Feb; 61(1):45-50. PubMed ID: 6858643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.
    de Vos D; Slee PH; Stevenson D; Briggs RJ
    Cancer Chemother Pharmacol; 1992; 31(1):76-8. PubMed ID: 1458563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.
    Osborne RJ; Malik ST; Slevin ML; Harvey VJ; Spona J; Salzer H; Williams CJ
    Br J Cancer; 1988 Jan; 57(1):115-6. PubMed ID: 3348944
    [No Abstract]   [Full Text] [Related]  

  • 34. Tamoxifen non-compliance: does it matter?
    Murthy V; Bharia G; Sarin R
    Lancet Oncol; 2002 Nov; 3(11):654. PubMed ID: 12424066
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.
    DeGregorio MW; Wilbur BJ; Coronado E; Osborne CK
    Cancer Chemother Pharmacol; 1987; 20(4):316-8. PubMed ID: 3690805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen dosage and bioequivalence: a correction.
    Mondzac AM
    J Clin Oncol; 1994 Sep; 12(9):1993-4. PubMed ID: 8083720
    [No Abstract]   [Full Text] [Related]  

  • 37. The metabolism of tamoxifen in human.
    Adam HK; Douglas EJ; Kemp JV
    Biochem Pharmacol; 1979; 28(1):145-7. PubMed ID: 758904
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal duration of adjuvant endocrine therapy: how to apply the newest data.
    Wimmer K; Strobl S; Bolliger M; Devyatko Y; Korkmaz B; Exner R; Fitzal F; Gnant M
    Ther Adv Med Oncol; 2017 Nov; 9(11):679-692. PubMed ID: 29344105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
    Severson TM; Nevedomskaya E; Peeters J; Kuilman T; Krijgsman O; van Rossum A; Droog M; Kim Y; Koornstra R; Beumer I; Glas AM; Peeper D; Wesseling J; Simon IM; Wessels L; Linn SC; Zwart W
    Oncotarget; 2016 Jun; 7(23):33901-18. PubMed ID: 27129152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.
    Dunphy MP; Lewis JS
    J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):106S-21S. PubMed ID: 19380404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.